The potential interest of topiramate in addictions

Thorens, Gabriel;Billieux, Joël;Manghi, Rita;Khan, Riaz;Zullino, Daniele Fabio;et.al.
(2011) Current Pharmaceutical Design — Vol. 17, n° 14, p. 1410-1415 (2011)

Files

No attached file found for this publication.

Details

Authors
  • Thorens, GabrielHopitaux Universitaires de Genève, Suisse
    Author
  • Billieux, JoëlUCLouvain
    Author
  • Manghi, RitaHopitaux Universitaires de Genève, Suisse
    Author
  • Khan, RiazHopitaux Universitaires de Genève, Suisse
    Author
  • Zullino, Daniele FabioHopitaux Universitaires de Genève, Suisse
    Author
Show more
Abstract
Topiramate is one of the currently most promising compounds in the field of addiction medicine. This paper discusses its potential utility related to a phase model of addiction development, focusing on the assumption that addiction is a continuous process involving different neurobiological pathways, depending on the stage of addiction. A specific emphasis will be made on the development of dysfunctional automatic behaviors in the late stage of addiction and the central role of glutamate and AMPA receptors. The aim is to propose that if too broad an effect of anti-addiction medication is expected (such as anti-craving, anti-relapse and preventive effects), the results might be disappointing. The speculative specific efficacy of topiramate in addiction is described.
Affiliations

Citations

Thorens, G., Billieux, J., Manghi, R., Khan, R., Khazaal, Y., & Zullino, D. F. (2011). The potential interest of topiramate in addictions. Current Pharmaceutical Design, 17(14), 1410-1415. https://doi.org/10.2174/138161211796150864 (Original work published 2011)